Summary

Overview
The global angiotensin ii receptor blockers market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Angiotensin II receptor blockers, or angiotensin II receptor antagonists, are medications used to treat hypertension and heart failure. They are also used to treat chronic kidney disease and are prescribed after a heart attack.
Candesartan, Losartan, and Valsartan are a few of them. An ARB is a drug whose name ends in "Sartan." Angiotensin II hormone actions are mitigated by RBs. Due to its significant blood artery constriction, this hormone raises blood pressure.
Further elevation of blood pressure is caused by angiotensin II's promotion of the body's retention of water and salt. When a hormone binds to certain receptors, like the AT1 receptors in blood vessels, the kidneys, heart, and kidneys, ARBs block that hormonal activation. The action of angiotensin II can be blocked to lower blood pressure and prevent renal and cardiac damage.
Market Dynamics: Drivers
Increasing Demand for Drugs to Treat High Blood Pressure and Heart Failure
Multiple factors drive the demand for the angiotensin ii receptor blockers market. Angiotensin II receptor blockers inhibit the effects of angiotensin II. It causes blood vessels to constrict, which can lead to hypertension. ARBs aid in expanding blood vessels, lowering blood pressure, and making it easier for the heart to pump blood.
Angiotensin II receptor blockers relax the veins and arteries, lowering blood pressure and making it easier for the heart to pump blood. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise blood pressure and make the heart work harder. To treat heart failure, drugs known as angiotensin receptor blockers (ARBs) such as losartan, candesartan, eprosartan, irbesartan, telmisartan, and valsartan are commonly used.
Heart failure is a major and growing public health issue. The overall prevalence of clinically identified heart failure is estimated to be 3?20 cases/1000 population, but this rises to more than 100 cases/1000 in those over 65. Hence, with the growing prevalence of heart failure, the global angiotensin II receptor blockers market is expected to grow.
The market for ARB II medications will also expand as a result of expanding initiatives by public and private institutions as well as increased global awareness of hypertension. The hypertension awareness emblem will be discontinued by Glenmark Pharmaceuticals in May 2022.
A hypertension awareness campaign was also conducted in India in May 2022 by the Namya Smile Foundation (NSF). The organization conducted a camp to check the blood pressure and made them aware of various aspects of high blood pressure.
Restraints
Factors such as the various side effects associated with angiotensin drugs, regulatory challenges, competition from substitutes, lack of awareness about the usage of medicine, drug recalls and competition from generic drugs are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The angiotensin ii receptor blockers market is segmented based on type, application, end-user, and region.
The valsartan segment accounted for approximately 43.2% of the angiotensin II receptor blockers market share
The Valsartan segment is expected to hold the largest market share over the forecast period. Valsartan, known as Diovan, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is an acceptable first-line treatment for high blood pressure. It is taken orally.
It is an angiotensin II receptor blocker used alone or in combination with other medications to treat hypertension and lower cardiovascular mortality after a heart attack. Valsartan is available in 40mg, 80mg, 160mg, and 320mg and is available as a hard capsule. Novartis manufactures brand-name drugs containing the active ingredient valsartan. Diovan, Diovan HCT, Entresto, Exforge, and Exforge HCT are their brand-name valsartan products.
Additionally, various strategies adopted by the key market players such as product launches and mergers and acquisitions support the market growth. In this Valsartans segment, other sartan drugs help to drive the market growth.
For instance, Hanmi Pharmaceutical declared in May 2022 that it will begin selling Amosartan, the popular medication for hypertension, in China under the Meiyaping brand. It was the first blood pressure combination medication produced domestically to be sold in China.
Dr.Reddy's launched Valsatan tables into the U.S. market. These individuals need treatment for heart failure and elevated blood pressure in December 2021. With this launch, Dr. Reddy's market share in the US market has increased and patients have access to a less expensive substitute for the FDA-approved brand drug Diovan.
Geographical Analysis
North America accounted for approximately 40.7% of the angiotensin ii receptor blockers market share
North America region is expected to hold the largest market share over the forecast period. The increasing prevalence of kidney disease, heart failure, and hypertension is expected to drive the market growth in this region.
For instance, according to the National Institute on Diabetes and Digestive and Kidney Diseases, chronic kidney disease (CKD) affects more than one in every seven adults in the United States, totaling an estimated 37 million people.
In April 2021, United Therapeutics Corporation announced that the United States Food and Drug Administration approved its drug for the treatment of pulmonary hypertension associated with interstitial lung disease, known as Tyvaso (Treprostinil).
In addition, as per the travel therapeutics press release in February 2023, IgAN is a rare kidney disease (RKD) and a leading cause of kidney failure due to glomerular disease, affecting up to 150,000 people in the U.S., with approximately 30,000 to 50,000 of such patients estimated to be addressable under the indication approved via accelerated approval.
CKD risk is even higher for Americans who have diabetes or high blood pressure, the two most common causes of kidney disease. Reducing blood pressure caused by systemic vasodilation with an ARB contributes to its beneficial effects in treating kidney disease. Furthermore, ARB-induced renal vasodilation increases renal blood flow, which improves renal ischemia and hypoxia.
Moreover, the increasing FDA approvals in this region are expected to drive market growth. For instance, on December 24th, 2021, Lupin received preliminary approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Azilsartan Medoxomil Tablets, 40 mg, and 80 mg, to market a generic equivalent of Edarbi Tablets.
The other factors such as increasing awareness among the people about hypertension in the region. For instance, in November 2021, New public service announcements (PSAs) were released by the American Heart Association (AHA), American Medical Association (AMA), HHS Office of Minority Health (OMH), Health Resources & Services Administration (HRSA), and the Ad Council to encourage people to take charge of their health by self-monitoring their blood pressure and talking with a healthcare provider about their numbers.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the angiotensin ii receptor blockers market. Angiotensin Receptor Blockers (ARBs) have significant pleiotropic protective effects in addition to their antihypertensive properties, including inflammation reduction. ARBs directly protect the lungs from severe acute respiratory syndrome caused by viral infections, including coronavirus infections.
ARB administration enhances ACE2's protective effect. For these reasons, ARB therapy must be maintained in patients with hypertension, diabetes, and renal disease, all of which are comorbidities of the current COVID-19 pandemic.
The ability of ARBs to reduce inflammation and endothelial and epithelial dysfunction in many organs is a significant benefit. ARBs directly protect the lung endothelial barrier integrity after acute injuries caused by many viruses. Hence, the angiotensin II receptor blockers market is expected to grow due to the COVID-19 impact.
Market Segmentation
By Type
- Valsartan
- Azilsartan
- Candesartan
- Eprosartan
- Irbesartan
- Losartan
- Olmesartan
- Telmisartan
- Others
By Application
- Heart Failure
- Hypertension
- Kidney Disease
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the angiotensin II receptor blockers market include Novartis AG, Daiichi Sankyo Co. Ltd, Lupin Ltd, Novartis AG, Takeda Pharmaceutical Co. Ltd, AstraZeneca, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim, Abbive Inc, Zydus Cadila among others.
Key Developments
- On March 26, 2024, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. has received approval for Entresto Granular Tablets for Pediatric Use 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, hereinafter referred to as Entresto Granular Tablets), an angiotensin receptor neprilysin inhibitor (ARNI).
- On February 17, 2023, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI (spartan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ?1.5 g/g.
- On February 16th, 2021, the FDA-approved Novartis Entresto (sacubitril/valsartan) helped to reduce the risk of cardiovascular hospitalization and death for heart failure in adult patients with chronic heart failure.

Why Purchase the Report?
- To visualize the angiotensin ii receptor blockers market segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of angiotensin ii receptor blockers market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The angiotensin ii receptor blockers market report would provide approximately 62 tables, 59 figures, and 182 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Demand of Drugs to Treat High Blood Pressure and Heart Failure
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Angiotensin II Receptor Blocker Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Valsartan*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Azilsartan
7.4. Candesartan
7.5. Eprosartan
7.6. Irbesartan
7.7. Losartan
7.8. Olmesartan
7.9. Telmisartan
7.10. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Heart Failure *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hypertension
8.4. Kidney Disease
8.5. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Ambulatory Surgical Centers
9.5. Other
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
• Daiichi Sankyo Co. Ltd
• Lupin Ltd
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca
• Sanofi S.A.
• Merck & Co., Inc.
• Boehringer Ingelheim
• Abbvie Inc
• Zydus Cadila
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us